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Background: The purpose of this study was to retrospectively com-
pare the volume doubling time (VDT) on serial computed tomogra-
phy (CT) of non–small-cell lung cancer (NSCLC) with epidermal 
growth factor receptor (EGFR) mutation with that of NSCLC with-
out the mutation.
Methods: One hundred and two pathologically proven NSCLCs, 
including 69 patients with lung adenocarcinoma, were reviewed with 
helical CT. Each tumor underwent at least two CT scans. The VDT 
was calculated using a modified Schwartz formula. EGFR mutations 
at exons 18–21 were determined by common fragment analysis and 
Cycleave method.
Result: The median VDT of all the patients was 188 days. EGFR 
mutations were noted in 35 of the 102 patients. The VDT in the 35 
patients with EGFR mutations (median 676 days) was longer than 
that in the 67 patients without EGFR mutations (median 139 days) 
(p <0.001). By histology subtype, the VDT of adenocarcinoma (305 
days) was longer than that of squamous cell carcinoma (81 days) and 
other types (90 days; p <0.001).
Conclusion: In NSCLC patients, positive EGFR mutation status may 
be associated with longer VDT, which seemed to have a slowly pro-
gressive and less-aggressive character. More accurate evaluation of 
VDT may be helpful for understanding the natural history of EGFR 
mutation–positive NSCLC and treatment with EGFR tyrosine kinase 
inhibitors.
Key Words: Volume doubling time, Epidermal growth factor recep-
tor mutation, Non–small-cell lung cancer.
(J Thorac Oncol. 2014;9: 1340–1344)
Because most patients with resectable non–small-cell lung cancer (NSCLC) are treated surgically soon after diagnosis, 
the natural history of pulmonary masses has not been adequately 
investigated. Because patients with incidentally detected small 
NSCLC are often symptom free and have lesions that are too 
small to be characterized, they sometimes refuse to undergo sur-
gical treatment or are left untreated with close follow-up.1
Many reports have been published in which the growth 
rates of lung cancer were estimated using chest radiograph.2,3 
The prognosis of lung cancer correlates with the volume 
doubling time (VDT) of the tumor on chest radiograph, and 
longer VDT is associated with better prognosis.2,4 Recently, 
a number of reports have been published on the use of com-
puted tomography (CT) to determine the growth rates of lung 
cancer.5–7 A short VDT indicates rapid growth, and a VDT of 
less than 400 days has been suggested as the best cutoff value 
to distinguish between an indolent and a malignant lesion.7–9 
In addition, VDT is a key parameter to distinguish aggressive 
cancers from slow-growing cancers.8
Recently, the usefulness of epidermal growth factor 
receptor-tyrosine kinase inhibitors (EGFR-TKIs) for NSCLC 
patients was reported.10–12 Therefore, evaluating the EGFR 
mutation status has become increasingly important for the 
treatment of NSCLC. Several clinicopathological factors pre-
dict EGFR mutation status, such as East-Asian populations, 
female sex, no smoking history, and adenocaricnoma.11–13 
Radiological findings have not been significantly deter-
mined as predictive of EGFR mutation status, or else such 
findings are controversial, for example, frequent findings of 
peripheral adenocarcinoma with predominantly ground-glass 
opacity(GGO)14 or frequent association with a smaller GGO 
ratio.15 If the imaging characteristics associated with EGFR 
mutation status can be determined, they could provide a use-
ful clinical predictor of EGFR mutation status in patients with 
unresectable lung cancer and unable to perform lung biopsy.
To our knowledge, however, no study has investigated 
the relationship between the VDT of the tumor and EGFR 
mutation status in NSCLC patients. We speculated that 
NSCLC in patients positive for EGFR mutations may have 
longer VDT than in those without the mutation. To examine 
this speculation, we performed a retrospective study.
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MATERIALS AND METHODS
Patients
This retrospective study was approved by the ethics 
committee of the Mito Medical Center Institutional Review 
Board. In our department, very small-sized tumors on initial 
chest CT scan were re-evaluated in 1 or 2 months to deter-
mine whether they increase in size or not. From February 
2006 through January 2013, a total of 102 NSCLC patients 
underwent at least two CT scans before surgery.
All the 102 surgically resected tumors were pathologi-
cally confirmed as NSCLC, including those from 69 patients 
with lung adenocarcinoma. Histological classification was 
determined according to the World Health Organization clas-
sification of lung tumors.16 The tumor, node, and metasta-
ses staging system of the 7th edition of the American Joint 
Committee for Cancer Staging System was used.17 Clinical 
information including the patient’s age, sex, smoking history, 
histology, pathological stage, tumor size, VDT and EGFR 
mutation status were collected for analysis.
CT Examinations and Measurement of Lesions
All CT scans were performed on a conventional or 
 thin-sliced CT (CT model until Mar 2010: SOMATOM 
EMOTION, Siemens, Erlangen, Germany; after April 2010: 
SOMATOM Definition As; Siemens). All 102 NSCLC tumors 
could be clearly visualized at the initial and final follow-up 
scans and analyzed on a picture archiving and communica-
tion system (Synapse; Fujifilm Medical Systems, Tokyo, 
Japan). Two thoracic surgeons blind to the result of the EGFR 
mutation status of each patient reviewed all the CT scans 
and calculated the VDT of each tumor. Size of the tumor on 
thin-slice CT scan was measured including the part of GGO 
lesion. The interval between the initial and final follow-up CT 
scans ranged from 14 to 2470 days (median, 143 days). All 
the tumors were enlarged on CT scan in this study period. The 
VDTs were calculated using a modification of the Schwartz 
formula of exponential growth (Fig.1).2,5,18,19
Detection of EGFR Mutations
For the gene mutation analysis, tumor specimens were 
obtained by surgical resection. All the specimens were fixed 
in formalin and embedded in paraffin. Genomic DNA was 
extracted from thick sections obtained from paraffin blocks. 
We performed EGFR mutation analyses of four tyrosine kinase 
domain (exons 18–21), which are frequently mutated in lung 
cancer, as previously described.13 The exon 19 deletion was 
determined by common fragment analysis using polymerase 
chain reaction (PCR). Other EGFR mutation were determined 
by the Cycleave real-time quantitative PCR technique using a 
Cycleave PCR core kit (Takara Bio, Ohtsu, Japan) with a point 
mutated-specific cycling probe, as previously described.20 All 
the EGFR mutation analyses were performed in a clinical lab-
oratory (SRL, Tokyo, Japan).
Data and Statistical Analysis
Statistical significance between the two groups was 
determined using the Mann–Whitney and χ2 tests. One-way 
analysis of variance was used to determine statistical sig-
nificance among the histology subtypes. Statistical analysis 
was performed using SPSS Statistics software (version 11.5; 
SPSS, Chicago, IL). Probability values less than 0.05 were 
considered to indicate significant differences.
RESULTS
The clinicopathological characteristics of the 102 
NSCLC patients are summarized in Table 1. All the patients 
were surgically treated, as follows: lobectomy in 76 patients, 
segmentectomy in 19 patients, and wedge resection in seven 
patients. The patients comprised 63 men (61.8%) and 39 
women (38.2 %). Their mean age was 71 years (range, 52–
87 years). Sixty-six of the patients (64.7%) were current or 
 ex-smokers. Sixty-nine patients (67.6%) had adenocarcinoma, 
23 (22.5%) had squamous cell carcinoma, and 10 (9.8%) had 
other histology types. EGFR mutations were detected in 35 of 
the 102 NSCLC patients (34.3%); 18 of these had the exon 
19 deletion and 17 had point mutations (exon 21 L858R:14 
patients; exon 18 G719X: 2 patients; exon 21 L861Q: 1 
patient). The median VDT of the total 102 NSCLC patients 
was 188 days (range, 24–9686 days).
Table 2 shows the characteristics of the patients with 
EGFR mutations. The mutations were significantly more fre-
quent in female patients (p = 0.006), patients with no history 
of smoking (p = 0.001), and patients with adenocarcinoma (p 
< 0.001). The maximum tumor sizes at the time of the ini-
tial measurement in the EGFR mutation–positive and –nega-
tive groups were 20.9 ± 11.7 mm (mean ± standard deviation 
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(mean ± SD; median: 21 mm; range, 6–90 mm), respectively. 
The maximum tumor sizes at the time of the preoperative 
CT in the EGFR mutation-positive and -negative groups 
were 25.4 ± 13.3 mm (mean ± SD; median: 22 mm; range, 
8–65 mm) and 31.2 ± 16.2 mm (mean ± SD; median: 28 mm; 
range, 9–97 mm), respectively. The median VDT in the 35 
patients with EGFR mutations was 676 days (range, 27–9686 
days), and that in the 67 patients without EGFR mutations was 
139 days (range, 25–3963 days), indicating a significant dif-
ference between them (p = 0.001). The VDT in the 33 patients 
with EGFR mutation positive adenocarcinoma (median: 676 
days; range, 27–9686 days) was longer than that in 36 patients 
with EGFR mutation negative adenocarcinoma (median: 200 
days; range, 44–3963 days; p = 0.014).
The VDT in the exon 19 mutant NSCLCs (median: 272 
days; range, 28–3061 days) was not longer than that in the 
exon 21 mutant NSCLCs (median: 817 days; range, 85–5159 
days; p= 0.166).
Table 3 shows the association between the clinicopatho-
logical factors of NSCLC and the VDT. There were signifi-
cant differences in sex (p = 0.004), smoking habit (p < 0.001), 
pathological stage (p = 0.003), and EGFR mutation status 
(p < 0.001). The median VDTs of the adenocarcinoma, squa-
mous cell carcinoma, and other histology types were 305 days, 
81 days, and 90 days, respectively, which were significantly 
different (p < 0.001).
DISCUSSION
To determine the natural history of pulmonary masses, 
most recent studies have investigated changes in VDT by mea-
suring pulmonary nodules detected on chest CT scan rather 
than those detected on chest radiograph.3,7,8 Tumor VDT helps 
to distinguish between benign and malignant lesions21 and is 
thought to provide a useful index of lung cancer aggressive-
ness.2,8 In addition, tumor VDT differed significantly among 
histology types. The VDT of adenocarcinoma was reported to 
be 200 to 400 days, whereas that of squamous cell carcinoma 
was approximately 100 days.5,8,18
Our data are similar in that the VDT of adenocarci-
noma was significantly longer than those of squamous cell 
carcinoma and other histology types. These results indicate 
that histology could be predicted by the VDT of the lung 
tumor. Some recent studies reported that a lung cancer with 
a VDT of more than 400 days indicates an indolent tumor.7,9 
In this study, the VDT was evaluated only in incidentally 
detected symptom-free tumors that were closely followed 
up. All the 102 tumors, which were pathologically con-
firmed as NSCLC, had a median VDT of 188 days. With 
regard to the EGFR mutation status, our results showed that 
EGFR mutation–positive NSCLC had longer VDT than did 
TABLE 1.  Characteristics of 102 Patients with Non–Small 
Cell Lung Cancer
Age (yrs) Mean: 71; range, 52–87
Sex
  Male 63 (61.8%)
  Female 39 (38.2%)
Smoking
  Current or ex-smoker 66 (64.7%)
  Nonsmoker 36 (35.3%)
Histology
  Adenocarcinoma 69 (67.6%)
  Squamous cell carcinoma 23 (22.5%)
  Others 10 (9.8%)
Pathological stage
  IA–B 80 (78.4%)
  IIA–B 12 (11.8%)
  IIIA 8 (7.8%)
  IV 2 (2.0%)
EGFR mutation
  Positive (mutated type) 35 (34.3%)
  Negative (wild type) 67 (65.7%)
Maximum tumor size
  At diagnosis Median: 20 mm (range, 6–90 mm)
Mean ± SD: 22.9 ± 13.7 mm
  At preoperative Median: 26 mm (range, 8–97 mm)
Mean ± SD: 29.2 ± 15.5 mm
Observation period between initial 
diagnosis to surgery
Median: 143 days (range, 14–2470 
days)
Mean ± SD: 409 ± 545 days
Volume doubling time median: 188 days (range, 24–9686 days)
Mean ± SD: 619 ± 1236 days




Positive Negative p value
Age, >65: 65 or younger 24:11 50:17 0.641
Sex, Male: female 15/20 48/19 0.006
Smoking smoker: nonsmoker 13/22 53/14 0.001
Histology <0.001
  Adenocarcinoma 33 36
  Squamous cell carcinoma 1 22
  Other 1 9
Pathological stage 0.082
  IA–B 31 49
  IIA–IV 4 18
Maximum tumor size
  Initial CT Median 18 mm 21 mm 0.218
Range 6–50 mm 6–90 mm
Mean ± SD 20.9 ± 11.7 mm 24.0 ± 14.6 mm
  Preoperative 
CT 
Median 22 mm 28 mm 0.029
Range 8–65 mm 8–97 mm
Mean ± SD 25.4 ± 13.3 mm 31.2 ± 16.2 mm
  Volume 
doubling 
time 
Median 676 days 139 days 0.001
Range 27–9686 days 24–3963 days
Mean ± SD 1173 ± 1829 
days
330 ± 607 days
CT, computed tomography; EGFR, epidermal growth factor receptor.
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EGFR mutation–negative NSCLC. This result suggests that 
EGFR mutation–positive NSCLC has a slowly progressive 
and less-aggressive character in the resectable lung cancer. 
Differences in VDT according to EGFR mutation status 
indicate that VDT may become a predictive factor of EGFR 
mutation status. Therefore, we supposed that VDT provides 
clinical information about both the EGFR mutation status of 
the tumor and its aggressiveness.
Some researchers reported predictability of EGFR 
mutation status in CT morphologic assessments of lung ade-
nocarcinoma with GGO.14,22 The VDT of GGO lesions was 
longer than that of other lesion types, including semisolid 
lesion and solid lesions.5,18 These results suggest an associa-
tion among VDT, GGO, and EGFR mutation status. However, 
other researchers insisted that EGFR mutation status is asso-
ciated with a smaller GGO ratio.15,23 In this study, we did not 
directly evaluate the relationships among VDT, GGO, and 
EGFR mutation status, and therefore, the association of EGFR 
mutation with GGO is beyond the scope of this study. Future 
studies will clarify the specific radiological characteristics that 
can predict EGFR mutation status.
The relationship between VDT and biological charac-
teristics has been reported in one article. Tilanus-Linthorst 
et al.24 investigated the effect of a breast cancer suscepti-
bility gene 1 (BRCA1) or breast cancer susceptibility gene 
2 (BRCA2) mutation on the growth rate of breast cancers. 
Growth was twice as fast in BRCA1 or BRCA2 patients as in 
high-risk patients of the same age, and the authors concluded 
that tumors grow quickly in women with BRCA1 mutations. 
To the best of our knowledge, however, no study has evaluated 
the relationship between VDT and EGFR mutation status.
Although the EGFR gene emerged as a potentially 
useful prognostic and predictive factor in the treatment of 
advanced NSCLC with EGFR-TKIs,10–13 the clinical and 
radiological features of NSCLC in patients with the EGFR 
gene are unknown.
Very recently, Wu et al.25 evaluated the frequent EGFR 
mutations in NSCLC presenting with miliary intrapulmonary 
carcinomatosis and concluded that NSCLC patients with mili-
ary intrapulmonary carcinomatosis at the initial diagnosis had 
higher rates of adenocarcinoma and EGFR mutations. Sekine 
et al.26 indicated that NSCLC patients with the EGFR exon 19 
deletion have a peculiar pattern of brain metastases charac-
terized by multiple small metastases with small brain edema. 
Accumulation of knowledge about the clinical features of 
lung cancer in patients with the EGFR gene will help develop 
an approach to individual patient management.
As mentioned above, VDT less than 400 days has been 
proposed as the best cutoff between indolent and malignant 
lesions.7–9 In the present study, we showed that the median 
VDT of EGFR mutation–positive NSCLC was 676 days 
(range, 27–9686 days). Further study will reveal whether 
these results indicate that NSCLCs with the EGFR mutation 
are indolent, and if so, whether we can select minimal surgical 
treatment for EGFR mutation–positive NSCLC patients who 
have severe comorbidity or who are very old.
Despite its novel findings, the current study has several 
limitations. Key among these are its retrospective nature and 
small sample size. Another limitation is a technical one: our 
study depended on conventional measurement methods on 
thin-slice CT scans, not semiautomatic computer-aided detec-
tion software that allows for volumetric  three-dimensional 
analysis of lung nodules.27 We showed that the VDT in 
adenocarcinoma was longer than that in nonadenocarci-
noma, therefore, this might have influenced the difference in 
VDT observed between EGFR-positive and EGFR-negative 
patients as nearly all EGFR-positive patients had adenocar-
cinoma. In this study, we also showed the results of the dif-
ference in VDT among patients with adenocarcinoma, which 
showed a significant difference in VDT between patients with 
or without EGFR mutation. In addition, there were nonadeno-
carcinoma patients with longer VDT than 200 days, though 
statistical analysis could not be performed because of small 
sample size. Therefore, we included patients with adenocarci-
noma and those with nonadenocarcinoma in this study. These 
findings suggested that the difference in histologic type was 
the only reason why there was the difference in VDT between 
patients with or without EGFR mutation. Our study did not 





(range, days) p value
Age, yrs 0.781
  >65 74 183(24–9686)
  ≤65 28 203(28–3963)
Sex 0.004
  Male 63 147(24–3081)
  Female 39 272(30–9686)
Smoking <0.001
  Smoker 66 147(24–3061)
  Nonsmoker 36 359(83–9686)
Histology <0.001
  Adenocarcinoma 69 305(27–9686)
  Squamous cell 
carcinoma
23 81(24–3061)
  Other 10 90(31–213)
Pathological stage 0.003
  IA–B 80 203(24–9686)
  IIA–IV 22 106(27–1541)
Tumor size
  Initial CT 0.107
   >30 mm 21 130(27–5158)
   ≤30 mm 81 208(24–9686)
Preoperative CT 0.011
  >30 mm 37 130(27–5158)
  ≤30 mm 65 217(24–9686)
EGFR mutation status <0.001
  Positive 35 676(27–9686)
  Negative 67 139(24–3963)
CT, computed tomography; EGFR, epidermal growth factor receptor; VDT, volume 
doubling time.
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not conclude these issues because of small sample size, and do 
believe that they can be clarified in future studies. Our study 
also has some important clinical implications for the manage-
ment of NSCLC patients. We showed that the VDT of EGFR 
mutation–positive NSCLC was longer than that of EGFR 
mutation–negative NSCLC.
Accumulation of knowledge of the specific radiologi-
cal findings of EGFR mutation–positive NSCLC will provide 
information on the less-aggressive character of the tumor 
and its responsiveness to EGFR-TKIs, which will lead to an 
 individual-treatment approach for patients. Regardless of its 
prediction of EGFR mutation status, the radiographic appear-
ance would potentially be a predictive factor of EGFR muta-
tion status in patients in whom a tissue sample cannot be 
obtained. More accurate assessment of the tumor growth rate 
and VDT may be helpful to understand the natural history of 
NSCLC and indications for appropriate therapy.
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